🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Press release for our new study🌍 Sylvester Comprehensive Cancer Center researchers uncover evolving global trends in lung cancer risk factors like tobacco, air pollution, and asbestos gilberto lopes Dr. Estela Rodriguez Samuel Kareff, MD, MPH Medical Data Research Collaborative Miami Hematology Oncology Program Director Ana S. Salazar, MD, MPHS Dan Morgenstern, MD, MSc : newswise.com/articles/study…

healthday.com/healthpro-news… gilberto lopes Dr. Estela Rodriguez Samuel Kareff, MD, MPH Medical Data Research Collaborative Dan Morgenstern, MD, MSc Ana S. Salazar, MD, MPHS Miami Hem/Onc Program Director Sylvester Comprehensive Cancer Center

Congrats Aman Chauhan huge unmet need and a pleasure to work with you and Seneca Therapeutics, Inc. on this!

#GI25🎤drop #NEST🪺🙋🏻‍♂️🙌🏽 |➖➖➖➖➖➖➖➖➖➖ 💯 | | | | | | | | |————————————————— ✅NO RECURRENCES📅! 💡Neoadjuvant immunotherapy keeps delivering! 👉🏽Patients with MSS🧊NOT just MSI-High🔥colorectal #cancer. Goal is to👏🏾*CURE*👏🏾more patients. 🔜Phase2/3 OncoAlert ASCO

Read about our study on Healio! Thank you, Healio Pulmonology , for helping further spread awareness about risk factors driving #lungcancer mortality. While tobacco-related deaths decline, the impact of particulate matter continues to rise. Sylvester Comprehensive Cancer Center Miami Hem/Onc Program Director gilberto lopes

Dr. Jordi Remon discusses uncommon #EGFR mutations in NSCLC at #ITCD2025. Afatinib approved here but osimertinib has some activity. Is using PACC a better approach to guiding therapies? Afatinib probably preferred for me in exon 18 but need to manage toxicity aggressively.

Grateful to @ascopost for featuring our article! Our momentum in tackling #tobacco-associated lung cancer must continue, but we also need to raise awareness and deepen our research on #airpollution and other risk factors related cancer. ASCO IASLC gilberto lopes Dr. Estela Rodriguez

Ph Ib Trial Ivonescimab (PD-1/VEGF bispecific)+Plt/Etop in 1L ES SCLC JTO & JTO CRR: - Ivo (3 dose levels)+plt/etopx4 ➡️ivo maintenance - 35pts, ORR 80%, DCR 91% - g3+ TRAEs 60% (⬇️ANC, WBC, Hb) Intriguing. VEGF not a traditional sclc target OncoAlert #LCSM jto.org/article/S1556-…

#mRNAvaccines for #PancreaticCancer (PDAC) PART4 1. Out today in nature nature.com/articles/s4158… 🧵👇🏽 [1/23]

Join us today at noon EST for free #PatientEducation to discuss all things new in the management of Colorectal Cancers Baptist Health Cancer Care Baptist Health Miami Cancer Institute Research #CRCSM #PatientEducation

The slide we have all been waiting for: OS in #MARIPOSA ▫️OS was significantly improved with amivantamab + lazertinib (HR 0.75) ▫️3 yr OS: 60% with amivantamab + lazertinib v 51% for osimertinib ▫️Curves appear to widen over time Oncology Brothers OncoAlert

Oncology Brothers OncoAlert Aakash Desai, MD, MPH, FASCO Fawzi Abu Rous, MD Bruna Pellini, MD Rafeh Naqash, MD Misty Dawn Shields Stephen V Liu, MD Rami Manochakian MD, FASCO Cancer Education Dr. Estela Rodriguez Xiuning Le MD PhD Jill Feldman EGFR Resisters EGFR Positive Lung Cancer UK Amivantamab’s biggest challenge has been its toxicity—the degree of OS benefit won’t translate in the real world without supportive measures. Kudos to the sponsor for investing in these (IMO) practice-changing supportive measures. BOOKMARK this slide! OncoAlert #ELCC25

We’re thrilled to welcome three new specialists to Baptist Health #LynnCancerInstitute: 🔹 Dr. Christine Pestana 🔹 Dr. Ross Taylor 🔹 Dr. Samuel Kareff These experts will help us provide cutting-edge cancer care. Learn more: BaptistHealth.net/LCI

And the fun starts! From @asco #asco25 press release Overall survival was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm. PFS pic below NEJM asco.org/about-asco/pre…

Alcohol and cancer in the US From Chinmay Jani @asco #asco25 Key Takeaway Points •Alcohol-associated cancer deaths have doubled in the USA •Disproportionate burden: Males and the 55+ age group. •Despite reduction in absolute mortality rates in some groups, proportional

This morning, I had the honor of presenting my first Rapid Oral at #ASCO25 🎤 — a truly unforgettable experience ✨. Our study highlights the rising burden of #alcohol-associated cancers 🍷🎗️ across sites, age groups, and sexes gilberto lopes Dr. Estela Rodriguez . Grateful to all my mentors

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

And of course: Lung Oral session @asco #asco25 #lcsm My take so far: Krystal 7 IO + adagrasib is interesting as it was tolerated, but efficacy does not seem to be better than with IO alone or with chemo. Will need to wait for and see randomized trial Dato shows interesting

Dr. Rafeh Naqash, MD walks us through DeLLphi-301 and ongoing BiTEs targeting #DLL3 . 🧠With tarlatamab, we cannot forget that ICANS can occur much later than what we see in heme malignancies 🧠ASCO #ASCO25 #lcsm #lcam #SCLC

Lurbinectedin + atezolizumab in 2L SCLC (an IIT 👏 ) shows: - ORR 40.4% (IO naive: 44.1%, IO experienced: 37.3%). Intriguing question regarding synergy. - mPFS 4.6 mo, mOS 10.1 mo - Sets the stage for IMforte phase III (to be presented during #ASCO25)